Mastodon

Glycine (Tablets) Instructions for Use

ATC Code

N07XX (Other drugs for the treatment of nervous system diseases)

Active Substance

Glycine (Rec.INN WHO registered)

Clinical-Pharmacological Group

A drug that improves brain metabolism

Pharmacotherapeutic Group

Other agents for the treatment of nervous system diseases

Pharmacological Action

An agent affecting brain metabolism, an essential amino acid. It is a central inhibitory neurotransmitter.

It improves metabolic processes in brain tissues and has a sedative and antidepressant effect.

It has glycinergic and GABA-ergic, α1-adrenoblocking, antioxidant, and antitoxic effects; regulates the activity of NMDA receptors and thereby reduces psychoemotional stress, aggressiveness, and conflict; improves social adaptation and mood, facilitates falling asleep, and normalizes sleep; increases mental performance; reduces the severity of vegetative-vascular disorders (including during menopause) and general cerebral disorders in ischemic stroke and traumatic brain injury, and the toxic effect of ethanol on the central nervous system.

It is effective as an auxiliary agent for epileptic seizures.

Pharmacokinetics

It easily penetrates most biological fluids and body tissues, including the brain.

It does not accumulate.

It is rapidly broken down in the liver by glycine oxidase to water and carbon dioxide.

Indications

As part of complex therapy: stress conditions, psychoemotional stress, reduced mental performance, behavioral disorders in children and adolescents, chronic alcoholism, interruption of binge drinking, the acute period of withdrawal syndrome, functional and organic lesions of the nervous system accompanied by increased excitability, emotional instability, decreased mental performance, and sleep disorders (including neuroses, neurosis-like states, encephalopathy of various origins, residual effects after brain and spinal cord injuries), ischemic stroke.

ICD codes

ICD-10 code Indication
F07 Personality and behavioral disorders due to disease, damage or dysfunction of the brain
F10.2 Chronic alcoholism
F10.3 Withdrawal state
F43 Reaction to severe stress and adjustment disorders
F48.0 Neurasthenia
F48.9 Unspecified neurotic disorder
F51.2 Nonorganic disorders of the sleep-wake schedule
F90.0 Disturbance of activity and attention
F91.9 Conduct disorder, unspecified
G92 Toxic encephalopathy
G93.4 Unspecified encephalopathy
I63 Cerebral infarction
I67.4 Hypertensive encephalopathy
R45.1 Restlessness and agitation
R45.8 Other symptoms and signs involving emotional state (suicidal thoughts (tendencies))
T90 Sequelae of injuries of head
T91.3 Sequelae of spinal cord injury
Z73.0 Burn-out
Z73.3 Stress, not elsewhere classified (physical and mental strain)
ICD-11 code Indication
6A05.Z Attention deficit hyperactivity disorder, with unspecified presentation
6A8Z Affective disorders, unspecified
6B4Z Disorders specifically associated with stress, unspecified
6B6Z Dissociative disorders, unspecified
6C40.2Z Alcohol dependence, unspecified
6C40.4Z Alcohol withdrawal syndrome, unspecified
6C40.Z Disorders due to alcohol use, unspecified
6C91.Z Dissocial behavioral disorder, unspecified
6E68 Secondary emotionally labile personality disorder
6E6Z Unspecified secondary mental or behavioral syndromes
7B2Z Sleep-wake cycle disorders, unspecified
8B11 Cerebral ischemic stroke
8B22.8 Hypertensive encephalopathy
8D43.0Y Other specified toxic encephalopathy
8D43.0Z Toxic encephalopathy, unspecified
8D44.Y Other specified alcohol-related neurological disorders
8E47 Encephalopathy, not elsewhere classified
8E4A.0 Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord
8E63 Post-cardiopulmonary bypass encephalopathy
MB22.0 Abulia
MB24.F Restlessness
MC4Y Other specified symptoms or signs involving the ear or mastoid process
ME66.Y Other specified skin changes
MF3Y Other specified symptoms, signs, or clinical findings related to the female genital system
MG23 Fear of death
MG24.00 Fear of malignant neoplasm of digestive organs
MG24.01 Fear of malignant neoplasm of breast
MG24.02 Fear of malignant neoplasm of male genital organs
MG24.0Y Other specified fear of cancer
MG24.0Z Fear of cancer, unspecified
MG24.1 Fear of human immunodeficiency virus
MG24.2 Fear of hematological disease
MG24.3 Fear of digestive system disease
MG24.4 Fear of eye diseases
MG24.5 Fear of heart disease
MG24.6 Fear of hypertensive disease
MG24.7 Fear of cardiovascular disease
MG24.8 Fear of musculoskeletal disease
MG24.9 Fear of neurological disease
MG24.A Fear of respiratory disease
MG24.B Fear of diseases of the endocrine system, nutritional disorders, or metabolic disorders
MG24.C Fear of diseases of the urinary system
MG24.D Fear of developing pregnancy complications
MG24.E Fear of a sexually transmitted disease in women
MG24.F Fear of a disease of the female genital organs or breast
MG24.G Fear of a sexually transmitted disease in men
MG24.H Fear of diseases of the male genital organs
MG24.Y Other specified fear of disease
MG24.Z Fear of disease, unspecified
NA0Z Head injury, unspecified
NB2Z Injury of nerves or spinal cord at thorax level, unspecified
NB6Z Injury of spinal cord at abdomen, lower back and pelvis level, unspecified
ND36 Other injuries involving multiple body regions, not elsewhere classified
ND51.Z Unspecified injuries of spine and trunk at unspecified level
NF2Z Unspecified injuries, poisonings or certain other consequences of external causes
QD85 Burn-out
QE01 Stress, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Tablets

It is used sublingually or buccally.

For psychoemotional stress, decreased memory, attention, mental performance, mental retardation, deviant behavior, 100 mg is prescribed 2-3 times/day for 14-30 days.

For functional and organic lesions of the nervous system accompanied by increased excitability, emotional lability, and sleep disorders, children under 3 years are prescribed 50 mg per dose 2-3 times/day for 7-14 days, then 50 mg once/day for 7-10 days. The daily dose is 100-150 mg, the course dose is 2000-2600 mg. Children over 3 years and adults are prescribed 100 mg 2-3 times/day, the course of treatment is 7-14 days. The course of treatment can be increased to 30 days; if necessary, the course is repeated after 30 days.

For sleep disorders, 50-100 mg is prescribed 20 minutes before sleep or immediately before sleep (depending on age).

For ischemic cerebral stroke, 1000 mg is prescribed within the first 3-6 hours from the onset of the stroke, then 1000 mg/day for 1-5 days, then 50-100 mg 3 times/day for the next 30 days.

In narcology, it is used as a means to increase mental performance and reduce psychoemotional stress during remission in cases of encephalopathy, organic lesions of the central and peripheral nervous system, 100 mg 2-3 times/day for 14-30 days. If necessary, the courses are repeated 4-6 times a year.

Adverse Reactions

Possible allergic reactions.

Contraindications

Children under 3 years of age (for some dosage forms), hypersensitivity to glycine.

Use in Pregnancy and Lactation

Use during pregnancy and breastfeeding is not recommended.

Pediatric Use

Use in children is possible in appropriate dosage forms.

Geriatric Use

No restrictions on use are indicated.

Special Precautions

In patients prone to arterial hypotension, doses should be reduced and blood pressure should be monitored; if it decreases, glycine use should be discontinued.

Drug Interactions

It reduces the toxic effect of anticonvulsants, antipsychotics, and antidepressants.

When combined with hypnotics, tranquilizers, and neuroleptics, the central nervous system inhibitory effect is additive.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Biotiki MNPK, LLC (Russia)

Dosage Form

Bottle OTC Icon Glycine Sublingual tablets 100 mg: 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white or almost white with marbled elements, round, flat-cylindrical, with a bevel and a score line.

1 tab.
Glycine microencapsulated 100 mg

Excipients: methylcellulose – 1 mg, magnesium stearate – 1 mg.

50 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (2) – cardboard packs.

Marketing Authorization Holder

Vertex, JSC (Russia)

Dosage Form

Bottle OTC Icon Glycine Sublingual tablets 100 mg: 10, 20 or 50 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white or almost white, round, flat-cylindrical in shape, with a bevel; marbling is allowed.

1 tab.
Glycine 100 mg

Excipients: methylcellulose – 1.3 mg, magnesium stearate – 0.7 mg.

5 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (1) – cardboard packs.
10 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (5) – cardboard packs.
20 pcs. – cardboard contour cell packs (1) – cardboard packs.
10 pcs. – jars (1) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Bottle OTC Icon Glycine Sublingual tablets 100 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white, with a score line on one side and a bevel on two sides; marbling is allowed.

1 tab.
Glycine 100 mg

Excipients: povidone (Kollidon 25) – 4 mg, magnesium stearate – 1 mg, microcrystalline cellulose – 5 mg.

50 pcs. – contour cell packs (1) – cardboard packs.

Marketing Authorization Holder

Tatkhimpharmpreparaty, JSC (Russia)

Dosage Form

Bottle OTC Icon Glycine Buccal and sublingual tablets 100 mg: 25, 50, 100, or 150 pcs.

Dosage Form, Packaging, and Composition

Buccal and sublingual tablets white, round, flat-cylindrical, with a bevel; slight marbling is allowed.

1 tab.
Glycine 100 mg

Excipients: microcrystalline cellulose, povidone K-25 (medium molecular weight polyvinylpyrrolidone), magnesium stearate.

10 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs (1) – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (4) – cardboard packs.
25 pcs. – contour cell packs (6) – cardboard packs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Bottle Rx Icon Glycine forte Buccal and sublingual tablets 250 mg: 10, 20, 30, 50, 60, 90, 100, 150, 270, or 300 pcs.

Dosage Form, Packaging, and Composition

Buccal and sublingual tablets white or almost white, round, flat-cylindrical, with a cross-shaped score line on one side and bevels on two sides; slight marbling of the surface is allowed.

1 tab.
Glycine 250 mg

Excipients: microcrystalline cellulose (MCC-101) – 80.65 mg, povidone K25 – 6.8 mg, magnesium stearate – 2.55 mg.

10 pcs. – cardboard contour cell packs – cardboard packs.
10 pcs. – cardboard contour cell packs (2) – cardboard packs.
10 pcs. – cardboard contour cell packs (3) – cardboard packs.
10 pcs. – cardboard contour cell packs (5) – cardboard packs.
10 pcs. – cardboard contour cell packs (9) – cardboard packs.
10 pcs. – cardboard contour cell packs (10) – cardboard packs.
30 pcs. – cardboard contour cell packs – cardboard packs.
30 pcs. – cardboard contour cell packs (2) – cardboard packs.
30 pcs. – cardboard contour cell packs (3) – cardboard packs.
30 pcs. – cardboard contour cell packs (5) – cardboard packs.
30 pcs. – cardboard contour cell packs (9) – cardboard packs.
30 pcs. – cardboard contour cell packs (10) – cardboard packs.

Marketing Authorization Holder

Canonpharma Production, CJS (Russia)

Dosage Form

Bottle OTC Icon Glycine Forte Buccal tablets 250 mg: 10, 20, 30, 50, 60, 90, or 100 pcs.

Dosage Form, Packaging, and Composition

Buccal tablets 1 tab.
Glycine 250 mg

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.

Marketing Authorization Holder

Promomed Rus LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Or

Biokhimik, JSC (Russia)

Dosage Forms

Bottle Rx Icon Glycine Forte Sublingual tablets 250 mg: 10, 20, 25, 30, 50, 75, 90, 100, 125, 225, or 250 pcs.
Sublingual tablets 250 mg: 10, 20, 30, 50, 90, or 100 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white or almost white, round, flat, with a cross-shaped score on one side and beveled edges on two sides; slight marbling is allowed.

1 tab.
Glycine 250 mg

Excipients: microcrystalline cellulose (type 101) – 134 mg, povidone – 12 mg, magnesium stearate – 4 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
25 pcs. – contour cell packs (1) – cardboard packs.
25 pcs. – contour cell packs (2) – cardboard packs.
25 pcs. – contour cell packs (3) – cardboard packs.
25 pcs. – contour cell packs (5) – cardboard packs.
25 pcs. – contour cell packs (9) – cardboard packs.
25 pcs. – contour cell packs (10) – cardboard packs.

Sublingual tablets white or almost white, round, flat, with a cross-shaped score on one side and beveled edges on two sides; slight marbling is allowed.

1 tab.
Glycine 250 mg

Excipients: microcrystalline cellulose (type 101) – 134 mg, povidone – 12 mg, magnesium stearate – 4 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (9) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – glass jars (1) – cardboard packs.
20 pcs. – glass jars (1) – cardboard packs.
30 pcs. – glass jars (1) – cardboard packs.
50 pcs. – glass jars (1) – cardboard packs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Bottle OTC Icon Glycine Ozon Sublingual tablets 50 mg: 10 or 50 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets 1 tab.
Glycine 50 mg

10 pcs. – contour cell packs (1) – cardboard packs.
50 pcs. – contour cell packs (1) – cardboard packs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Bottle OTC Icon Glycine Renewal Buccal and sublingual tablets 100 mg: 20, 28, 30, 50, 56, 60, 100, 105, 120 or 200

Dosage Form, Packaging, and Composition

Buccal and sublingual tablets white or almost white, round, flat-cylindrical, with a bevel; marbling may be present.

1 tab.
Glycine 100 mg

Excipients: methylcellulose – 1 mg, magnesium stearate – 1 mg.

10 pcs. – cardboard cell packs (2) – cardboard packs.
10 pcs. – cardboard cell packs (3) – cardboard packs.
10 pcs. – cardboard cell packs (5) – cardboard packs.
10 pcs. – cardboard cell packs (10) – cardboard packs.
14 pcs. – cardboard cell packs (2) – cardboard packs.
14 pcs. – cardboard cell packs (4) – cardboard packs.
15 pcs. – cardboard cell packs (4) – cardboard packs.
15 pcs. – cardboard cell packs (7) – cardboard packs.
20 pcs. – cardboard cell packs (3) – cardboard packs.
20 pcs. – cardboard cell packs (6) – cardboard packs.
20 pcs. – cardboard cell packs (10) – cardboard packs.

Marketing Authorization Holder

Ozon, LLC (Russia)

Dosage Form

Bottle OTC Icon Glycine-Bio Sublingual tablets 100 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white, with a score on one side and beveled edges on two sides; marbling may be present.

1 tab.
Glycine 100 mg

Excipients: povidone (kollidon 25) – 4 mg, magnesium stearate – 1 mg, microcrystalline cellulose – 5 mg.

50 pcs. – contour cell packs (1) – cardboard packs.

Marketing Authorization Holder

Canonpharma Production, CJS (Russia)

Dosage Form

Bottle Rx Icon Glycine-Canon Buccal tablets 1000 mg: 5, 10 or 20 pcs.

Dosage Form, Packaging, and Composition

Buccal tablets 1 tab.
Glycine 1000 mg

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.
5 pcs. – contour cell packs (4) – cardboard packs.

Marketing Authorization Holder

N.A. Semashko Moscow Chemical Pharmaceutical Preparations, JSC (Russia)

Dosage Form

Bottle OTC Icon Glycine-MHFP Sublingual tablets 100 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Sublingual tablets white; marbling may be present.

1 tab.
Glycine 100 mg

Excipients: methylcellulose (methylose) – 1.3 mg, magnesium stearate – 0.7 mg.

10 pcs. – contour cell packs (5) – cardboard packs.

Table of Contents

→ TABLE OF CONTENTS